Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis

Study investigated the effectiveness of central nervous system treatment with methotrexate combined with immunochemotherapy for treatment of high risk diffuse large b-cell lymphoma.